{
  "docId": "019de071-3aad-716d-87e6-57feca2aeaf3",
  "docSlug": "2b4775a08c8e376708f38bde257340c9",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 39,
  "pageCount": 42,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "appendix_data",
  "function": "appendix",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Includes a visual representation of market expansion for gMG.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-3aad-716d-87e6-57feca2aeaf3/39",
  "deckHref": "/decks/019de071-3aad-716d-87e6-57feca2aeaf3",
  "deckJsonHref": "/decks/019de071-3aad-716d-87e6-57feca2aeaf3.json",
  "deckAnchorHref": "/decks/019de071-3aad-716d-87e6-57feca2aeaf3#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.3,
        "x": 0.67,
        "y": 0.78
      },
      "kind": "callout",
      "text": "Opportunity to revolutionise treatment in Wilson Disease",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c98a3c1-a871-45fb-98ce-f3f8074d9d80",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.62,
        "x": 0.03,
        "y": 0.78
      },
      "kind": "callout",
      "text": "Compelling product profile and value proposition will help expand addressable gMG population",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef8a37e5-58c0-4cce-9557-6349aeede68b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.48,
        "w": 0.24,
        "x": 0.38,
        "y": 0.25
      },
      "kind": "image",
      "text": "Addressable gMG market expansion diagram",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3efd3a8-2783-43da-ad39-001b6a719b27",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.28,
        "x": 0.68,
        "y": 0.23
      },
      "kind": "list",
      "text": "ALXN1840 Wilson Disease: Phase III read-out anticipated H2 2021; Novel potential new treatment; Powered for superiority; Potential for rapid control",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34987a41-4668-464f-b039-d7ea8d726ff2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.31,
        "x": 0.04,
        "y": 0.23
      },
      "kind": "list",
      "text": "Ultomiris gMG (2nd-generation, long-acting C5 inhibitor): Positive Phase III read-out July 2021; Regulatory submission to follow in H2 2021 and H1 2022",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "456bb052-c7f8-42be-94b6-44e528d9e174",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. Generalised myasthenia gravis.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27948ce5-b67e-41b1-82e5-3a724daa6b79",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Appendix: Rare Diseases - a new growth area for AstraZeneca",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9bbd6d21-33ac-4523-88e5-f77d42d16443",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.55,
        "x": 0.03,
        "y": 0.11
      },
      "kind": "title",
      "text": "Recent and upcoming pipeline developments",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25a25977-80c6-4903-993a-b60210b95483",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}